Avutometinib and Defactinib in Diffuse Gastric Cancer

The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.

Trial Details

NCT ID
NCT06487221
Phase
PHASE2
Sponsor
Ryan H. Moy, MD, PhD
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Avutometinib
  • Defactinib
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histologic or cytologic evidence of gastric/gastroesophageal junction carcinoma, classified as diffuse type, poorly cohesive, signet ring cell, or …
  • Prior therapy with at least one line of therapy for unresectable/metastatic disease, which must include platinum and fluoropyrimidine.
  • ECOG performance status of 0 or 1
  • Age ≥ 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →